Rate ratios for the achievement of physical activity recommendations and all cause mortality in the female and male cohorts
| Characteristic | No of subjects (%) | Deaths (n (%)) | RR* (95% CI) | RR† (95% CI) | RR‡ (95% CI) | No of subjects (%)** | Deaths (n (%)) | RR§ (95% CI) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *Crude. | ||||||||||||||||||
| **The sample was reduced for multivariate analysis because of non-responses for several covariates at baseline. | ||||||||||||||||||
| †Adjusted for the other recommendation. | ||||||||||||||||||
| ‡Age adjusted and adjustment for the other recommendation; for the combined measurement the result is age adjusted. | ||||||||||||||||||
| §Multivariate adjustment for age, other recommendation, social class, smoking, body mass index, cardiovascular risk factor index, alcohol intake, chronic disease index, and dietary factors. | ||||||||||||||||||
| ¶Recommendation for MPA: at least 2.5 hours a week of moderately intense physical activity representing 30 minutes on five days a week. | ||||||||||||||||||
| **Recommendation for VPA: one hour a week of vigorously intense physical activity corresponding to 20 minutes on three days a week. | ||||||||||||||||||
| Female cohort | ||||||||||||||||||
| Recommendation for MPA¶ | ||||||||||||||||||
| No | 1242 (36.1) | 290 (23.3) | 1 (referent) | 1 (referent) | 1 (referent) | 1220 (35.8) | 146 (12.0) | 1 (referent) | ||||||||||
| Yes | 2203 (63.9) | 353 (16.0) | 0.56 (0.44 to 0.70) | 0.63 (0.50 to 0.80) | 0.62 (0.49 to 0.79) | 2185 (64.2) | 151 (6.9) | 0.65 (0.51 to 0.82) | ||||||||||
| Recommendation for VPA** | ||||||||||||||||||
| No | 2454 (71.2) | 249 (10.1) | 1 (referent) | 1 (referent) | 1 (referent) | 2419 (71.0) | 246 (10.2) | 1 (referent) | ||||||||||
| Yes | 991 (28.8) | 51 (5.1) | 0.50 (0.37 to 0.67) | 0.57 (0.42 to 0.78) | 0.70 (0.51 to 0.95) | 986 (29.0) | 51 (5.2) | 0.78 (0.57 to 1.08) | ||||||||||
| Recommendation for MPA¶ or VPA** | ||||||||||||||||||
| No | 1089 (31.6) | 141 (12.9) | 1 (referent) | 1 (referent) | 1068 (33.4) | 138 (12.9) | 1 (referent) | |||||||||||
| Yes | 2356 (68.4) | 159 (6.7) | 0.51 (0.40 to 0.63) | 0.55 (0.44 to 0.69) | 2337 (68.6) | 159 (6.8) | 0.60 (0.47 to 0.75) | |||||||||||
| Male cohort | ||||||||||||||||||
| Recommendation for MPA¶ | ||||||||||||||||||
| No | 1533 (41.0) | 290 (18.9) | 1 (referent) | 1 (referent) | 1 (referent) | 1524 (40.9) | 288 (18.9) | 1 (referent) | ||||||||||
| Yes | 2209 (59.0) | 353 (16.0) | 0.83 (0.70 to 0.97) | 0.98 (0.83 to 1.15) | 0.86 (0.73 to 1.02) | 2201 (59.1) | 352 (16.0) | 0.90 (0.77 to 1.01) | ||||||||||
| Recommendation for VPA** | ||||||||||||||||||
| No | 2366 (63.2) | 484 (20.5) | 1 (referent) | 1 (referent) | 1 (referent) | 2354 (62.2) | 481 (20.4) | 1 (referent) | ||||||||||
| Yes | 1376 (36.8) | 159 (11.6) | 0.54 (0.45 to 0.65) | 0.54 (0.45 to 0.66) | 0.66 (0.54 to 0.79) | 1371 (36.8) | 159 (11.6) | 0.74 (0.61 to 0.90) | ||||||||||
| Recommendation for MPA¶ or VPA** | ||||||||||||||||||
| No | 1242 (33.2) | 262 (21.1) | 1 (referent) | 1 (referent) | 1234 (33.1) | 260 (21.1) | 1 (referent) | |||||||||||
| Yes | 2500 (66.8) | 381 (15.2) | 0.70 (0.60 to 0.82) | 0.71 (0.60 to 0.83) | 2491 (66.9) | 380 (15.3) | 0.80 (0.68 to 0.94) | |||||||||||